Predisposing factors in sulphasalazine-induced systemic lupus erythematosus

British Journal of Rheumatology

Volumn 36, Issue 10, 1997, Pages 1089-1094

  Gunnarsson, I ^a   Kanerud, L ^b   Pettersson, E ^a   Lundberg, I ^a   Lindblad, S ^a   Ringertz, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Drug induced SLE; SLE; Sulphasalazine

Indexed keywords

ACYLTRANSFERASE; ANTINUCLEAR ANTIBODY; DNA ANTIBODY; HISTONE ANTIBODY; HLA A1 ANTIGEN; HLA DQ ANTIGEN; SALAZOSULFAPYRIDINE;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; FEMALE; GENOTYPE; HAPLOTYPE; HLA SYSTEM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; NEPHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

EID: 0030724065     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.10.1089     Document Type: Article

References (39)

1. Griffiths ID, Kane SP. Sulphasalazine-induced lupus syndrome in ulcerative colitis. Br Med J 1977;6096:1188-9.
2. Jaup BH. Salazosulfapyridin-induziertes lupus-erythematodes-syndrom bei colitis ulcerosa. Dtsch Med Wochenschr 1978;103:1211-3.
3. Crisp AJ, Hoffbrand BI. Sulphasalazine-induced systemic lupus erythematosus in a patient with Sjögren's syndrome. J R Soc Med 1980;73:60-1.
4. Carr-Locke DL. Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease. Am J Gastroenterol 1982;77:614-6.
5. Rafferty P, Young AC, Haeney MR. Sulphasalazine- induced cerebral lupus erythematosus. Postgrad Med J 1982;58:98-9.
6. Vanheule BA, Carswell F. Sulphasalazine-induced systemic lupus erythematosus in a child. Eur J Pediatr 1983;140:66-8.
7. Clementz GL, Dolin BJ. Sulfasalazine-induced lupus erythematosus. Am J Med 1988;84:535-8.
8. Deboever G, Devogelaere R, Holvoet G. Sulphasalazine-induced lupus-like syndrome with cardiac tamponade in a patient with ulcerative colitis. Am J Gastroenterol 1989;84:85-6.
9. Wildhagen K, Hartung K, Hammer M, Mau W, Schmidt RE, Deicher H et al. Drug-related lupus in a patient with rheumatoid arthritis under sulfasalazine treatment. Clin Rheumatol 1993;12:265-7.
10. Siam AR, Hammoudeh M. Sulfasalazine induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Rheumatol 1993;20:207.
11. Borg AA, Davis MJ, Dawes PT, Shadforth MF. Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus. Clin Rheumatol 1994;13:522-4.
12. Walker EM, Carty JE. Sulphasalazine-induced systemic lupus erythematosus in a patient with erosive arthritis. Br J Rheumatol 1994;33:175-6.
13. Caulier M, Dromer C, Andrieu V, Le Guennec P, Fournie B. Sulfasalazine induced lupus in rheumatoid arthritis. J Rheumatol 1994;21:750-1.
14. Hill ME, Gordon C, Situnayake RD, Heath DA. Sulfasalazine induced seizures and dysphasia. J Rheumatol 1994;21:748-9.
15. Bray VJ, West SG, Schultz KT, Boumpas DT, Rubin RL. Antihistone antibody profile in sulfasalazine induced lupus. J Rheumatol 1994;21:2157-8.
16. Laversuch CJ, Collins DA, Charles PJ, Bourke BE. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol 1995;34:435-9.
17. Khattak FH, Morris IM, Mattingly PC. Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. Br J Rheumatol 1996;35:104.
18. Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5.
19. Reidenberg MM, Drayer DE, Lorenzo B, Strom BL, West SL, Snyder ES et al. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum 1993;36:971-3.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Smith CA, Wadelius M, Gough AC, Harrison, DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyl transferase-2 polymorphism validated by phenotyping with isoniazid. J Med Genet, in press.
23. Olerup O, Olsson R, Hultcrantz R, Broome U. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995;108:870-8.
24. Snyderman, R. Humoral immunity. In: Utsinger PD, Zvaifler NJ, Ehrlich GE, eds. Rheumatoid arthritis. Philadelphia: J B Lippincott, 1985:245.
25. Cohen MG, Webb J. Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis 1987;46:853-8.
26. Ragsdale CG, Petty RE, Cassidy JT, Sullivan DB. The clinical progression of apparent juvenile rheumatoid arthritis to systemic lupus erythematosus. J Rheumatol 1980;7:50-5.
27. Molin L, Larsson R, Karlsson E. Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases. Acta Med Scand 1977;201:217-222.
28. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 1994;20:61-86.
29. Carpenter CB. The major histocompatibility complex. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Principles of internal medicine. New York: McGraw-Hill 1994:385.
30. Batchelor JR, Welsh KI, Tinoco RM, Dollerty CT, Hughes GR, Bernstein R et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980;8178:1107-9.
31. Russell GI, Bing RF, Jones JA, Thurston H, Swales JD. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype. Q J Med 1987;65:845-52.
32. Black CM, Welsh KI, Fielder A, Hughes GR, Batchelor JR. HLA antigens and Bf allotypes in SLE: evidence for the association being with specific haplotypes. Tissue Antigens 1982;19:115-20.
33. Skarsvåg S, Hansen KE, Holst A, Moen T. Distribution of HLA class II alleles among Scandinavian patients with systemic lupus erythematosus (SLE): an increased risk of SLE among non[DRB1*03, DQA1*0501, DQB1*0201] class II homozygotes? Tissue Antigens 1992;40:128-33.
34. Davies EJ, Hillarby MC, Cooper RG, Hay EM, Green JR, Shah S et at. HLA-DQ, DR and complement C4 variants in systemic lupus erythematosus. Br J Rheumatol 1993;32:870-5.
35. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994;91:8562-6.
36. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995;101:428-35.
37. Hagiwara E, Gourley MF, Lee S, Klinman DM. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum 1996;39:379-385.
38. Danis VA, Franic GM, Rathjen DA, Laurent RM, Brooks PM. Circulating cytokine levels in patients with rheumatoid arthritis; results of a double blind trial with sulphasalazine. Ann Rheum Dis 1992;51:946-950.
39. Elliott MJ, Maini RN, Feldman M, Long-Fox A, Charles P, Katsikis P et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum 1993;36:1681-90.